Cambridge Investment Research Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.86M | Sell |
4,591
-241
| -5% | -$164K | 0.01% | 1410 |
|
|
2026
Q1 | $3.73M | Sell |
4,832
-58
| -1% | -$44.4K | 0.01% | 1137 |
|
|
2025
Q4 | $3.77M | Buy |
4,890
+869
| +22% | +$590K | 0.01% | 1081 |
|
|
2025
Q3 | $2.26M | Buy |
4,021
+116
| +3% | +$65.6K | 0.01% | 1407 |
|
|
2025
Q2 | $2.05M | Sell |
3,905
-15
| -0.4% | -$8.37K | 0.01% | 1418 |
|
|
2025
Q1 | $2.49M | Sell |
3,920
-410
| -9% | -$282K | 0.01% | 1209 |
|
|
2024
Q4 | $3.08M | Sell |
4,330
-1,014
| -19% | -$851K | 0.01% | 1077 |
|
|
2024
Q3 | $5.62M | Buy |
5,344
+163
| +3% | +$181K | 0.02% | 741 |
|
|
2024
Q2 | $5.45M | Sell |
5,181
-59
| -1% | -$57.2K | 0.02% | 710 |
|
|
2024
Q1 | $5.04M | Sell |
5,240
-2,883
| -35% | -$2.74M | 0.02% | 736 |
|
|
2023
Q4 | $7.13M | Sell |
8,123
-2,003
| -20% | -$1.65M | 0.03% | 547 |
|
|
2023
Q3 | $8.33M | Buy |
10,126
+5,832
| +136% | +$4.58M | 0.04% | 436 |
|
|
2023
Q2 | $3.08M | Sell |
4,294
-1,487
| -26% | -$1.15M | 0.01% | 909 |
|
|
2023
Q1 | $4.75M | Sell |
5,781
-632
| -10% | -$477K | 0.02% | 655 |
|
|
2022
Q4 | $4.63M | Sell |
6,413
-710
| -10% | -$524K | 0.02% | 637 |
|
|
2022
Q3 | $4.91M | Sell |
7,123
-2,529
| -26% | -$1.59M | 0.03% | 578 |
|
|
2022
Q2 | $5.71M | Sell |
9,652
-283
| -3% | -$184K | 0.03% | 531 |
|
|
2022
Q1 | $6.94M | Sell |
9,935
-651
| -6% | -$412K | 0.03% | 508 |
|
|
2021
Q4 | $6.68M | Buy |
10,586
+513
| +5% | +$315K | 0.03% | 535 |
|
|
2021
Q3 | $6.1M | Sell |
10,073
-1,825
| -15% | -$1.13M | 0.03% | 525 |
|
|
2021
Q2 | $6.65M | Buy |
11,898
+417
| +4% | +$211K | 0.03% | 507 |
|
|
2021
Q1 | $5.43M | Sell |
11,481
-2,246
| -16% | -$1.09M | 0.03% | 530 |
|
|
2020
Q4 | $6.63M | Buy |
13,727
+2,823
| +26% | +$1.52M | 0.04% | 421 |
|
|
2020
Q3 | $6.1M | Sell |
10,904
-3,981
| -27% | -$2.41M | 0.04% | 406 |
|
|
2020
Q2 | $9.28M | Buy |
14,885
+6,622
| +80% | +$3.76M | 0.07% | 269 |
|
|
2020
Q1 | $4.04M | Sell |
8,263
-3,694
| -31% | -$1.52M | 0.04% | 429 |
|
|
2019
Q4 | $4.49M | Buy |
11,957
+188
| +2% | +$63.3K | 0.03% | 505 |
|
|
2019
Q3 | $3.27M | Sell |
11,769
-1,483
| -11% | -$439K | 0.03% | 571 |
|
|
2019
Q2 | $4.15M | Buy |
13,252
+1
| +0% | +$333 | 0.04% | 466 |
|
|
2019
Q1 | $5.44M | Buy |
13,251
+495
| +4% | +$204K | 0.05% | 347 |
|
|
2018
Q4 | $4.76M | Buy |
12,756
+1,463
| +13% | +$535K | 0.05% | 339 |
|
|
2018
Q3 | $4.56M | Sell |
11,293
-654
| -5% | -$249K | 0.04% | 398 |
|
|
2018
Q2 | $4.12M | Buy |
11,947
+479
| +4% | +$150K | 0.04% | 392 |
|
|
2018
Q1 | $3.95M | Buy |
11,468
+2,166
| +23% | +$753K | 0.04% | 385 |
|
|
2017
Q4 | $3.5M | Buy |
9,302
+256
| +3% | +$104K | 0.04% | 403 |
|
|
2017
Q3 | $4.04M | Buy |
9,046
+6,387
| +240% | +$3.04M | 0.05% | 321 |
|
|
2017
Q2 | $1.31M | Sell |
2,659
-122
| -4% | -$53.4K | 0.02% | 680 |
|
|
2017
Q1 | $1.08M | Buy |
2,781
+259
| +10% | +$96K | 0.02% | 693 |
|
|
2016
Q4 | $926K | Sell |
2,522
-113
| -4% | -$43K | 0.02% | 717 |
|
|
2016
Q3 | $1.06M | Sell |
2,635
-112
| -4% | -$44.9K | 0.02% | 655 |
|
|
2016
Q2 | $959K | Buy |
2,747
+620
| +29% | +$239K | 0.02% | 618 |
|
|
2016
Q1 | $767K | Sell |
2,127
-87
| -4% | -$35.9K | 0.02% | 683 |
|
|
2015
Q4 | $1.2M | Buy |
2,214
+38
| +2% | +$20.6K | 0.03% | 496 |
|
|
2015
Q3 | $1.01M | Buy |
2,176
+1,199
| +123% | +$644K | 0.03% | 473 |
|
|
2015
Q2 | $498K | Sell |
977
-440
| -31% | -$215K | 0.01% | 809 |
|
|
2015
Q1 | $640K | Buy |
1,417
+55
| +4% | +$23.3K | 0.02% | 679 |
|
|
2014
Q4 | $559K | Sell |
1,362
-104
| -7% | -$40.9K | 0.02% | 720 |
|
|
2014
Q3 | $529K | Buy |
+1,466
| New | +$491K | 0.02% | 800 |
|
|
2014
Q2 | – | Sell |
-810
| Closed | -$243K | – | 1368 |
|
|
2014
Q1 | $243K | Buy |
+810
| New | +$250K | 0.01% | 1047 |
|
Other funds holding REGN
Cambridge Investment Research Advisors's REGN Position: Q2 2026 in Review
Cambridge Investment Research Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 5% in Q2 2026, selling an estimated $164K and leaving 4,591 shares worth $2.86M. The position accounts for 0.01% of the portfolio, ranked #1410.
Cambridge Investment Research Advisors first reported a position in REGN in Q1 2014 and has held it in 49 quarters since. The position peaked at $9.28M in Q2 2020. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Cambridge Investment Research Advisors held 4,591 shares of Regeneron Pharmaceuticals worth $2.86M as of Q2 2026.
- Cambridge Investment Research Advisors sold 241 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $164K.
- Regeneron Pharmaceuticals made up 0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1410 holding.
- Cambridge Investment Research Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2014 and has held it in 49 quarters since.
- Cambridge Investment Research Advisors's Regeneron Pharmaceuticals position peaked at $9.28M in Q2 2020.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.